Evidence map›Paper›PMID 38847244›Full record

ArticleCurrent cancer drug targets2025

Low Expression of GRIM-19 Correlates with Poor Prognosis in Patients with Upper Urinary Tract Urothelial Carcinoma.

Feng Tian, Long Lv, Zonglin Liu, Sheng Guan, Fengze Jiang, Qi Wang, Dhan V Kalvakolanu, Sixiong Jiang, Weibing Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Feng TianKey Laboratory of Microenvironment Regulation and Immunotherapy of Urinary Tumors of Liaoning Province, Department of Urology, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, Liaoning, China.
Long LvKey Laboratory of Microenvironment Regulation and Immunotherapy of Urinary Tumors of Liaoning Province, Department of Urology, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, Liaoning, China.
Zonglin LiuDepartment of Urology, Anshan Tumor Hospital, Anshan, 114000, Liaoning, China.
Sheng GuanKey Laboratory of Microenvironment Regulation and Immunotherapy of Urinary Tumors of Liaoning Province, Department of Urology, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, Liaoning, China.
Fengze JiangKey Laboratory of Microenvironment Regulation and Immunotherapy of Urinary Tumors of Liaoning Province, Department of Urology, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, Liaoning, China.
Qi WangKey Laboratory of Microenvironment Regulation and Immunotherapy of Urinary Tumors of Liaoning Province, Department of Urology, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, Liaoning, China.
Dhan V KalvakolanuDepartment of Microbiology and Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD21201, USA.
Sixiong JiangKey Laboratory of Microenvironment Regulation and Immunotherapy of Urinary Tumors of Liaoning Province, Department of Urology, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, Liaoning, China.
Weibing SunKey Laboratory of Microenvironment Regulation and Immunotherapy of Urinary Tumors of Liaoning Province, Department of Urology, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, Liaoning, China.

Funding

Guidance Plan of Natural Science Foundation of Liaoning Province 2019-ZD-0942Medical Science Research Project of Dalian 1912035National Natural Science Foundation of China 62376050, 81472392
6 · The paper itself

Abstract

purposeThis study aimed to clarify the expression of a gene associated with Retinoid- Interferon-Induced Mortality-19 (GRIM-19) in Upper Urinary Tract Urothelial Carcinoma (UUTUC) and its prognostic significance for UUTUC patients. MATERIALS AND

methodsImmunohistochemical (IHC) staining was used to determine the GRIM-19 expression in 70 paired samples. Progression-Free Survival (PFS) and Cancer-Specific Survival (CSS) were assessed using the Kaplan-Meier method. The independent prognostic factors for PFS and CSS were analyzed by multivariable Cox regression models.

resultsIHC staining showed that GRIM-19 expression was significantly decreased in UUTUC, and its cellular location changed from being both cytoplasmic and nuclear to only cytoplasmic. Kaplan- Meier analysis revealed that the patients with tumors expressing low GRIM-19 had a significantly higher risk for tumor progression (P = 0.002) and cancer-specific mortality (P < 0.001) compared to those with high GRIM-19 levels. The Cox regression showed that both GRIM-19 expression (P = 0.025) and lymph node metastasis (LN) (P = 0.007) were independent predictors of progression in the muscle-invasive (MIC) subgroup. GRIM-19 expressions (entire cohort: P = 0.011; MIC subgroup: P = 0.025), LN (entire cohort: P = 0.019; MIC subgroup: P = 0.007), and progression (entire cohort: P < 0.001; MIC subgroup: P < 0.001) were independent predictors of cancer-specific survival.

conclusionLow expression of GRIM-19 in patients with UUTUC had significantly shorter PFS or CSS compared to those with high GRIM-19-expressing tumors. High GRIM-19 expression was also strongly associated with longer PFS in MIC patients. It indicates that GRIM-19 might serve as a promising prognostic biomarker for UUTUC patients.

Indexed as

Apoptosis Regulatory ProteinsBiomarkers, TumorCarcinoma, Transitional CellNADH, NADPH OxidoreductasesUrologic NeoplasmsAdultAgedAged, 80 and overFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisApoptosis Regulatory ProteinsBiomarkers, TumorNADH, NADPH OxidoreductasesNDUFA13 protein, humanBiomarkergene associated with retinoid-interferon induced mortality-19immunohistochemistrylymph node metastasis.prognosisupper urinary tract urothelial carcinoma

Identifiers

PMID38847244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.